Valuation: Libra Infusions Limited

Market Cap 1.53B 190B 1.37B 1.27B 1.15B 2.14B 146B 2.18B 15.12B 6.03B 76.43B 5.76B 5.63B 242B P/E 2016
131x
P/E 2017 107x
Enterprise Value 2.43B 301B 2.17B 2.01B 1.82B 3.39B 231B 3.45B 23.93B 9.55B 121B 9.11B 8.92B 383B EV / Sales 2016
6.88x
EV / Sales 2017 6.34x
Free-Float
99%
Yield 2016
0.41%
Yield 2017 0.57%
1 day+1.44%
1 week+19.37%
Current month+5.34%
1 month+6.67%
3 months-6.30%
6 months-3.51%
Current year-5.46%
1 week 508.3
Extreme 508.3
623.8
1 month 501
Extreme 501
623.8
Current year 501
Extreme 501
739
1 year 501
Extreme 501
739
3 years 501
Extreme 501
1,125
5 years 435
Extreme 435
1,146.67
10 years 238.33
Extreme 238.333332
1,146.67
Manager TitleAgeSince
Chief Executive Officer - 1976-02-01
Director of Finance/CFO - -
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member - 2011-06-20
Chairman - 2013-02-12
Director/Board Member - 2011-06-20
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%+19.37%-14.62%-44.93% 10.88M
+3.41%+11.57%+68.25%+151.16% 1,224B
+0.27%+4.55%+45.90%+87.59% 662B
+1.89%+3.48%+29.52%+108.31% 514B
+0.42%+3.20%+54.15%+67.18% 388B
+2.59%+3.03%+73.47%+45.76% 361B
+1.12%+4.52%+35.30%+58.08% 302B
+6.96%+8.86%+11.27%+36.62% 271B
+2.20%+7.17%+61.22%+78.86% 249B
+3.89%+10.04%+44.98%+120.79% 205B
Average +2.46%+3.44%+40.94%+70.94% 417.69B
Weighted average by Cap. +2.39%+3.04%+51.44%+98.92%

Financials

2016 2017
Net sales 238M 29.56B 213M 197M 178M 333M 22.68B 338M 2.35B 937M 11.87B 894M 875M 37.59B 244M 30.32B 219M 202M 183M 342M 23.26B 347M 2.41B 961M 12.17B 917M 897M 38.56B
Net income 5.82M 722M 5.21M 4.81M 4.35M 8.14M 554M 8.27M 57.38M 22.89M 290M 21.84M 21.38M 919M 6.09M 755M 5.45M 5.03M 4.55M 8.51M 579M 8.65M 59.99M 23.93M 303M 22.84M 22.35M 961M
Net Debt 880M 109B 788M 727M 658M 1.23B 83.76B 1.25B 8.67B 3.46B 43.84B 3.3B 3.23B 139B 894M 111B 801M 739M 669M 1.25B 85.14B 1.27B 8.81B 3.52B 44.56B 3.36B 3.28B 141B
Logo Libra Infusions Limited
Libra Infusions Ltd is a Bangladesh-based company engaged in the manufacturing of Intravenous (I.V.) fluid. The Company's products include LIBOTT, LIBOTT-10, LIBOTT-25, LIBOTT-S, LIBOTT-S JR, NORMASOL, BABY SALINE, DIASOL, HARTSOL, LIBRAZOL, LIBRACIN, LIBOTT-M, LIBRACIN-400, and LIBRET. Its products are used in medical situations involving diarrheal disease, surgical operation, loss of blood, weakness and hospitalization in general. LIBOTT is used for rehydration in a time of water deficit, general weakness and post-surgical intervention. LIBOTT-10 is used for the treatment of jaundice, general weakness, eclampsia and pre-eclampsia. LIBOTT-25 is used in the emergency treatment of severe hypoglycemia. LIBOTT-S is used for rehydration during general weakness, water deficiency along with sodium, diuresis, intoxication and post-surgical intervention. LIBOTT-S JR fulfills the water deficit along with low deficiency of sodium chloride and supplies energy for growing children.
Employees
699
Date Price Change Volume
26-10-29 BDT 599.60 +1.44% 11,242
26-10-28 BDT 591.10 -1.32% 5,307
26-10-27 BDT 599.00 +3.22% 52,554
26-10-26 BDT 580.30 +7.48% 3,611
  1. Stock Market
  2. Stocks
  3. LIBRAINFU Stock